• 1
    Gershon MD. Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20(Suppl. 7): 314.
  • 2
    Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 165764.
  • 3
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 16519.
  • 4
    Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists a the non-classical 5-HT4 receptor positively coupled to adenylate cyclase in neurons. Naunyn Schmiedeberg's Arch Pharmacol 1989; 340: 40310.
  • 5
    Blondel O, Gastineau M, Dahmoune Y, Langlois M, Fischmeister R. Cloning, expression and pharmacology of four human 5-hydroxytryptamine4 receptor isoforms produced by alternative splicing in the caboxyterminus. J Neurochem 1998; 70: 225261.
  • 6
    Claeysen S, Faye P, Sebben M, Taviaux S, Bockaert J, Dumuis A. 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 1998; 861: 4956.
  • 7
    Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 63151.
  • 8
    Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000; 131: 92732.
  • 9
    Baxter GS, Craig DA, Clarke DE. 5-hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmeideberg's Arch Pharmacol 1991; 343: 43946.
  • 10
    Kilbinger H, Wolf D. Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 2705.
  • 11
    Kilbinger H, Gebquer A, Haas J, Ledinsky H, Rizzi CA. Benzimidazolenes and tenzapride facilitate qcetylcholive release from guinea pig myenteric plekusvia 5-HT4 receptors, Naunyn Schmiedbeng's Arch Pharmacol. 1995; 351: 22936.
  • 12
    LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum. Neurogastroenterol Motil 2004; 16: 35564.
  • 13
    Grider JR, Kuemmerle JF, Jin J-G. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1P receptors on sensory CGRP neurons. Am J Physiol 1996; 270: G77882.
  • 14
    Galligan JJ, Pan H, Messori E. Signalling mechanism coupled to 5-hydroxytryptamine4 receptor-mediated facilitation of fast synaptic transmission in the guinea-pig ileum myenteric plexus. Neurogastroenterol Motil 2003; 15: 5239.
  • 15
    Buchheit K-H, Gamse R, Giger R, Hoyer D, Klein F, Kloppner E, Pfannkuche H-J, Mattes H. The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995; 38: 23318.
  • 16
    Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004; 143: 54960.
  • 17
    Grider JR, Foxx-Orenstein AE, Jin J-G. 5-hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human rat and guinea pig intestine. Gastroenterology 1998; 115: 37080.
  • 18
    Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999; 288: 937.
  • 19
    Prins NH, Van Haselen JFWR, Lefebvre RA, Briejer MR, Akkermans LMA, Schuurkes JAJ. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999; 127: 14317.
  • 20
    Wardle KA, Sanger GJ. The guinea pig distal colon – a sensitive preparation for the investigation of 5-HT4 mediated contractions. Br J Pharmacol 1993; 110: 15939.
  • 21
    Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, Hanson RB, Fett SL, Zinsmeister AR. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280: 12706.
  • 22
    Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1: CD003960.
  • 23
    Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S, Bertold R, Maecke H, Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 174551.
  • 24
    Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003; 18: 10317.
  • 25
    Lyford G, Foxx-Orenstein A. Chronic intestinal pseudoobstruction. Curr Treat Options Gastroenterol 2004; 7: 31725.
  • 26
    Sanger GJ. Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol 1987; 91: 7787.
  • 27
    Craig DA, Clarke DE. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4receptor activation. Br J Pharmacol 1991; 102: 5634.
  • 28
    Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 100712.
  • 29
    Eglen RM, Swank SR, Walsh LKM and Whiting RL. Characterization of 5-HT3 and ‘‘atypical’’ 5-HT receptors mediating guinea pig ileal contractions. Br J Pharmacol 1990; 101: 51320.
  • 30
    Pan H, Galligan JJ. 5-HT1A and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons. Am J Physiol 1994; 266: G23080.
  • 31
    Kilbinger H, Gebauer A, Haas J, Ladinsky H, Rizzi CA. Benzimidazolones and renzapride facilitate acetylcholine release from guinea pig myenteric plexus via 5-HT4 receptors. Naunyn Schmeideberg's Arch Pharmacol 1995; 351: 22936.
  • 32
    Song CW, Lee KY, Kim CD, Chang TM, Chey WY. Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs. J Pharmacol Exp Ther 1997; 281: 13126.
  • 33
    Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, Baxter K, Zinsmeister AR. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895904.
  • 34
    Meyers NL, Palmer RM, George A. Efficacy and safety of renzapride in patients with constipation-predominant IBS: A Phase IIb study in the UK Primary Healthcare Setting. Gastroenterology 2004; 126: A640.
  • 35
    Henderson JC, Palmer MJ, Meyers NL, Spiller RC. A Phase IIb clinical study of renzapride in mixed-symptom (alternating) irritable bowel syndrome. Gastroenterology 2004; 126: A644.
  • 36
    Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991; 5: 13542.
  • 37
    Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 18699.
  • 38
    Itoh Z. Motilin and clinical application. Peptides 1997; 18: 593608.
  • 39
    Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, O'Neill G, Van Der Ploeg LH, Evans J, Patchett AA, Smith RG, Howard AD. Receptor for motilin identified in the human gastrointestinal system. Science 1999; 284: 21848.
  • 40
    Depoortere I, Peeters TL. Transduction mechanism of motilin and motilides in rabbit duodenal smooth muscle. Regul Pept 1995; 55: 22735.
  • 41
    Huang J, Zhou H, Mahavadi S, Sriwai W, Lyall V, Murthy KS. Signaling pathways mediating gastrointestinal smooth muscle contraction and MLC20 phosphorylation by motilin receptors. Am J Physiol 2005; 288: G2331.
  • 42
    Tack J, Janssens J, Vantrappen G, Peeters T, Annese V, Depoortere I, Muls E, Bouillon R. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992; 103: 729.
  • 43
    Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98: 25963.
  • 44
    Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49: 395401.
  • 45
    Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Staessen D, Mack RJ. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 165361.
  • 46
    Piessevaux H, Tack J, Wilmer A, Coulie B, Geubel A, Janssens J. Perception of changes in wall tension of the proximal stomach in humans. Gut 2001; 49: 2038.
  • 47
    Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002; 51: 612.
  • 48
    Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001; 49: 3178.
  • 49
    Frossard JL, Spahr L, Queneau PE, Giostra E, Burckhardt B, Ory G, DeSaussure P, Armenian B, De Peyer R, Hadengue A. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology 2002; 123: 1723.
  • 50
    Booth CM, Heyland DK, Paterson WG. Gastrointestinal promotility drugs in the critical care setting: a systematic review of the evidence. Crit Care Med 2002; 30: 142935.
  • 51
    Borovicka J, Kreiss C, Asal K, Remy B, Mettraux C, Wells A, Read NW, Jansen JB, D'Amato M, Bischof-Delaloye A, Fried M, Schwizer W. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol 1996; 271: G44853.
  • 52
    McLaughlin J, Grazia-Lucà M, Jones MN, D'Amato M, Dockray GJ, Thompson DG. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 1999; 116: 4653.
  • 53
    Grider JR, Makhlouf GM. Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am J Physiol 1990; 259: G18490.
  • 54
    Raybould HE, Roberts ME, Dockray GJ. Reflex decreases in intragastric pressure in response to cholecystokinin in rats. Am J Physiol 1987; 253: G16570.
  • 55
    Hölzer P, Turkelson CM, Solomon TE, Raybould HE. Intestinal lipid inhibits gastric emptying via CCK and a vagal capsaicin-sensitive afferent pathway in rats. Am J Physiol 1994; 267: G6259.
  • 56
    Coffin B, Fossati S, Flourie B, Lemann M, Jouet P, Franchisseur C, Jian R, Rambaud JC. Regional effects of cholecystokinin octapeptide on colonic phasic and tonic motility in healthy humans. Am J Physiol 1999; 276: G76772.
  • 57
    O'Brien MD, Camilleri M, Thomforde GM, Wiste JA, Hanson RB, Zinsmeister AR. Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit. Dig Dis Sci 1997; 42: 2633.
  • 58
    Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499506.
    Direct Link:
  • 59
    Varga G, Balint A, Burghardt B, D'Amato M. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004; 141: 127584.
  • 60
    Morton MF, Welsh NJ, Tavares IA, Shankley NP. Pharmacological characterization of cholecystokinin receptors mediating contraction of human gallbladder and ascending colon. Regul Pept 2002; 105: 5964.
  • 61
    Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Fried M. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997; 41: 5004.
  • 62
    Feinle C, D'Amato M, Read NW. Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distention and duodenal lipid. Gastroenterology 1996; 110: 137985.
  • 63
    Scarpignato C, Kisfalvi I, D'Amato M, Varga G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther 1996; 10: 4119.
  • 64
    Danzer M, Jocic M, Samberger C, Painsipp E, Bock E, Pabst MA, Crailsheim K, Schicho R, Lippe IT, Holzer P. Stomach-brain communication by vagal afferents in response to luminal acid back diffusion, gastrin, and gastric acid secretion. Am J Physiol 2004; 286: G40311.
  • 65
    Lal S, McLaughlin J, Barlow J, D'Amato M, Giacovelli G, Varro A, Dockray GJ, Thompson DG. Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol 2004; 287: G729.
  • 66
    Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 34755.
  • 67
    D'Amato M, Whorwell PJ, Thompson DG, Spiller RC, Giacovelli G, Rovati LC. The CCK-1 receptor antagonist dexloxiglumide. Am J Gastroenterology 2001; 96(Suppl. 96): S316.
  • 68
  • 69
    Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16(Suppl. 2): 1728.
  • 70
    Bartho L, Holzer P, Lembeck F. Is ganglionic transmission through nicotinic receptors essential for the peristaltic reflex in the guinea-pig ileum? Neuropharmacology 1987; 26: 16636.
  • 71
    Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 64971.
  • 72
    Delaney CP. Clinical perspective on postoperative ileus and the effect of opiates. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 616.
  • 73
    Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994; 37: 22625.
  • 74
    Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr. ADL 8–2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001; 69: 6671.
  • 75
    Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001; 345: 93540.
  • 76
    Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 72834.
  • 77
    Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedeberg's Arch Pharmacol 2002; 366: 381416.
  • 78
    Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999; 20: 27986.
  • 79
    Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73: 95390.